Abstract 871: Unveiling the potential of bispecific antibodies: A comprehensive analysis of efficiency, toxicity, and repurposing in cancer treatment

Abstract Bispecific antibodies have emerged as promising candidates for cancer treatment, prompting the necessity for a comprehensive understanding of their potential efficacy and toxicity across various cancer types. Leveraging single cell sequencing data, we systematically evaluated the efficacy and toxicity of all cell surface gene pairs across multiple cancers. First, we found that gene pairs involved in successful bispecific antibodies phase I/II clinical trials exhibited significantly higher efficacy scores and lower toxicity scores than gene pairs in those that failed, underscoring the utility of our method in selecting high-quality bispecific pairs. Second, to facilitate the identification of new pairs, we established baseline efficacy and toxicity scores based on successful phase I/II clinical trials, employing these scores to assess the potential of novel combinations. We systematically identified both cancer type-specific and pan-cancer candidate new bispecific antibody pairs. This extensive analysis not only provides valuable insights into the potential of bispecific antibodies to broaden the spectrum of cancer treatments, but also yields a highly confident list of candidate gene pairs capable of constructing effective bispecific antibodies. Citation Format: Binbin Wang, Sanna Madan, Alejandro Schaffer, Eytan Ruppin. Unveiling the potential of bispecific antibodies: A comprehensive analysis of efficiency, toxicity, and repurposing in cancer treatment abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 871.